title: [Blood concentrations of futraful, uracil and 5-fluorouracil (5-FU) after UFT administration in the various reconstructions after gastrectomy. Saitama UFT Research Group].
abstract: The study was undertaken in the total of 58 gastric cancer patients among which 17 of Billroth (BI), 14 of Billroth II (B II) anastomosis after subtotal gastrectomy, and 7 of jejunal interposition, 9 of double tract and 11 of Roux en Y anastomosis after total gastrectomy were included. Blood samples were taken before 200 mg of per oral UFT administration and after 1, 2, 3, 5 and 7hrs. consecutively. The blood Futraful (FT) level in the total gastrectomy groups reached peak concentration within 1hr and kept in relatively high level during the observation period of 7hrs. The time to maximum FT concentration delayed in almost of B I and a few of B II patients. The concentration curves of uracil (URA) and 5-FU were similar in shape, revealing steep increase and decrease except B I anastomosis which showed gentle course. The plotted maximum concentrations of URA and 5-FU in the every type of reconstruction showed a significant correlation in the regression line. In the analysis of AUC, URA/FT was under 10%, suggesting the longer retention of the unmetabolite type of FT and early disappearance of URA. The ratio of 5-FU/FT was indifferent in each reconstruction. 5-FU/URA was higher in subtotal rather than total gastrectomy groups. From the data obtained, blood concentration of 5-FU after UFT administration was considered to depend on the emptying status in the gastrectomies. And moreover, it depended on blood URA level, since FT from which 5-FU was derived, was kept still sufficiently remained during observation period.
authors.affiliation: Division of abdominal Surgery, Saitama Cancer Center Hospital, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Suda
authors.forename: K
authors.initials: K
authors.lastname: Uchida
authors.forename: H
authors.initials: H
authors.lastname: Okamura
authors.forename: Y
authors.initials: Y
authors.lastname: Oshima
authors.forename: M
authors.initials: M
authors.lastname: Shimizu
authors.forename: T
authors.initials: T
authors.lastname: Miyakawa
authors.forename: S
authors.initials: S
authors.lastname: Okubo
authors.forename: E
authors.initials: E
authors.lastname: Shiina
authors.forename: Y
authors.initials: Y
authors.lastname: Hosoda
authors.forename: Y
authors.initials: Y
authors.lastname: Tokura
mesh_terms: D000713:Anastomosis, Roux-en-Y; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000493:pharmacokinetics; D017024:Chemotherapy, Adjuvant; D005472:Fluorouracil / Q000097:blood*; D005743:Gastrectomy / Q000379:methods; D006801:Humans; D011184:Postoperative Period; D013274:Stomach Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D014498:Uracil / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics
chemical_list: D005641:Tegafur; D014498:Uracil; D005472:Fluorouracil